Literature DB >> 17343921

The impaired response of NK cells from HIV-infected progressor patients to A-class CpG oligodeoxynucleotides is largely dependent of a decreased production of IL-12.

Raquel Saez1, Pilar Echaniz, Maria Dolores De Juan, Jose Antonio Iribarren, Emilio Cuadrado.   

Abstract

We have reported that NK cells from HIV-infected progressors showed a markedly lower IFN-gamma production in response to an A-class CpG oligodeoxynucleotide as compared to LTNP subjects and healthy HIV-negative individuals. This functional defect was not related to the number of circulating plasmacytoid dendritic cells, nor to the alpha-interferon secreted. In contrast, defective response correlated negatively with the frequency of myeloid dendritic cells. Furthermore, peripheral blood mononuclear cells from LTNPs as well as those from some healthy HIV-negative donors secreted large amounts of IL-12 in unstimulated cultures and in response to the CpG-ODN whereas, HIV-progressor cells showed impaired responses and low level of spontaneous secretion. The addition of a monoclonal anti-IL-12 reduced the response to the CpG-ODN in a dose-dependent manner. These results suggest that the impaired response of NK cells to the CpG-ODN in HIV-progressors is largely dependent on a decreased production of IL-12.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17343921     DOI: 10.1016/j.imlet.2007.01.006

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  2 in total

1.  Delivery System of CpG Oligodeoxynucleotides through Eliciting an Effective T cell Immune Response against Melanoma in Mice.

Authors:  Wei Sun; Mingli Fang; Yajing Chen; Zhaogang Yang; Yue Xiao; Min Wan; Hua Wang; Yongli Yu; Liying Wang
Journal:  J Cancer       Date:  2016-01-05       Impact factor: 4.207

Review 2.  The Role of Innate Immunity in Natural Elite Controllers of HIV-1 Infection.

Authors:  Yuting Shi; Jinming Su; Rongfeng Chen; Wudi Wei; Zongxiang Yuan; Xiu Chen; Xinwei Wang; Hao Liang; Li Ye; Junjun Jiang
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.